QC
CHRS icon

Quadrature Capital’s Coherus Oncology CHRS Stock Holding History

Quadrature Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,775
Closed -$30K – 1646
2026
Q1 		$30K Buy
+17,775
New +$31.6K ﹤0.01% 1304
2025
Q4 		– Sell
-18,172
Closed -$29.7K – 1300
2025
Q3 		$29.7K Buy
+18,172
New +$20.2K ﹤0.01% 977

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Quadrature Capital's CHRS Position: Q2 2026 in Review

Quadrature Capital sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 17,775 shares — an estimated $30K sold.

Quadrature Capital first reported a position in CHRS in Q3 2025 and held it in 2 quarters. The position peaked at $30K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Quadrature Capital reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 17,775 Coherus Oncology shares in Q2 2026, an estimated $30K.
  • Quadrature Capital first reported a position in Coherus Oncology in Q3 2025 and held it in 2 quarters.
  • Quadrature Capital's Coherus Oncology position peaked at $30K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.